| CPC A61K 31/05 (2013.01) [A61K 9/7023 (2013.01)] | 16 Claims |
|
1. A pharmaceutical composition comprising a highly purified cannabis which comprises at least about 90% (w/w) cannabidiol (CBD), in a dosage form for transdermal delivery wherein the pharmaceutical composition comprises:
a concentration of the highly purified CBD selected from the group consisting of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, and about 15% w/w;
about 5% to about 25% w/w of a solvent comprising propylene glycol;
about 1% to about 20% w/w of a penetration enhancer comprising oleic acid;
about 0.1 to 0.7% of butylated hydroxytoluene;
about 2% to about 15% w/w of at least one suspending agent comprising silicon dioxide; and
about 50% to about 80% w/w of a silicone pressure sensitive adhesive,
wherein the pH of the composition is maintained at approximately 4.0 to 8.0,
wherein the pharmaceutical composition is in the form of a transdermal matrix patch, further wherein the pharmaceutical composition provides a constant rate of delivery of the active components of the matrix patch in a therapeutic range in a patient over at least 7 days.
|